siRNA-targeting transforming growth factor-β type I receptor reduces wound scarring and extracellular matrix deposition of scar tissue.

Hypertrophic scarring is related to persistent activation of transforming growth factor-β (TGF-β)/Smad signaling. In the TGF-β/Smad signaling cascade, the TGF-β type I receptor (TGFBRI) phosphorylates Smad proteins to induce fibroblast proliferation and extracellular matrix deposition. In this study, we inhibited TGFBRI gene expression via TGFBRI small interfering RNA (siRNA) to reduce fibroblast proliferation and extracellular matrix deposition. Our results demonstrate that downregulating TGFBRI expression in cultured human hypertrophic scar fibroblasts significantly suppressed cell proliferation and reduced type I collagen, type III collagen, fibronectin, and connective tissue growth factor (CTGF) mRNA, and type I collagen and fibronectin protein expression. In addition, we applied TGFBRI siRNA to wound granulation tissue in a rabbit model of hypertrophic scarring. Downregulating TGFBRI expression reduced wound scarring, the extracellular matrix deposition of scar tissue, and decreased CTGF and α-smooth muscle actin mRNA expression in vivo. These results suggest that TGFBRI siRNA could be applied clinically to prevent hypertrophic scarring.

[1]  B. Hinz,et al.  Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. , 2001, Molecular biology of the cell.

[2]  J. Pulido,et al.  RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. , 2004, Molecular vision.

[3]  Ye-yang Li,et al.  Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. , 2009, Burns : journal of the International Society for Burn Injuries.

[4]  W. Liu,et al.  Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. , 2001, Plastic and reconstructive surgery.

[5]  H. Levinson,et al.  A Review of Scar Scales and Scar Measuring Devices , 2010, Eplasty.

[6]  Mostofa A Hena,et al.  Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring. , 2012, Bioorganic & medicinal chemistry letters.

[7]  J. Gauthier,et al.  Inhibition of TGF‐β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine‐induced liver fibrosis , 2005 .

[8]  C. Profyris,et al.  Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part II. Strategies to reduce scar formation after dermatologic procedures. , 2012, Journal of the American Academy of Dermatology.

[9]  Chung Lee,et al.  Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-beta receptor II. , 2007, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[10]  B. Coulomb,et al.  Mechanisms of pathological scarring: Role of myofibroblasts and current developments , 2011, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[11]  D. Abraham,et al.  Activation of Key Profibrotic Mechanisms in Transgenic Fibroblasts Expressing Kinase-deficient Type II Transforming Growth Factor-β Receptor (TβRIIΔk)* , 2005, Journal of Biological Chemistry.

[12]  T. Doetschman,et al.  Wound healing in the transforming growth factor‐β1—deficient mouse , 1995, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[13]  R. Behringer,et al.  Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. , 2007, Arthritis and rheumatism.

[14]  Stephen M Warren,et al.  Inhibition of Smad3 expression in radiation-induced fibrosis using a novel method for topical transcutaneous gene therapy. , 2010, Archives of otolaryngology--head & neck surgery.

[15]  Youxin Jin,et al.  Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. , 2007, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[16]  George,et al.  Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. , 1998, The American journal of pathology.

[17]  J. Au,et al.  Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.

[18]  Hans C. Korting,et al.  Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies , 2011, Molecular medicine.

[19]  Jianing Zhang,et al.  Inhibition of TGF-β1-receptor posttranslational core fucosylation attenuates rat renal interstitial fibrosis. , 2013, Kidney international.

[20]  Y. Sheen,et al.  Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug , 2008 .

[21]  Thomas A. Mustoe, MD, FACS,et al.  Hypertrophic scar model in the rabbit ear: a reproducible model for studying scar tissue behavior with new observations on silicone gel sheeting for scar reduction , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[22]  M. Akagawa,et al.  Cinnamon extract promotes type I collagen biosynthesis via activation of IGF-I signaling in human dermal fibroblasts. , 2012, Journal of agricultural and food chemistry.

[23]  R. D. du Bois,et al.  Constitutive ALK5-Independent c-Jun N-Terminal Kinase Activation Contributes to Endothelin-1 Overexpression in Pulmonary Fibrosis: Evidence of an Autocrine Endothelin Loop Operating through the Endothelin A and B Receptors , 2006, Molecular and Cellular Biology.

[24]  Y. Chu,et al.  A Novel Truncated TGF-β Receptor II Downregulates Collagen Synthesis and TGF-β I Secretion of Keloid Fibroblasts , 2008, Connective tissue research.

[25]  Daniel B Longley,et al.  c-FLIP: a key regulator of colorectal cancer cell death. , 2007, Cancer research.

[26]  Andrew Leask,et al.  TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  S. Ledbetter,et al.  The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. , 2005, Journal of the American College of Surgeons.

[28]  P. Khaw,et al.  Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. , 1999, Investigative ophthalmology & visual science.

[29]  Bo Liu,et al.  ADAMTS-7 Mediates Vascular Smooth Muscle Cell Migration and Neointima Formation in Balloon-Injured Rat Arteries , 2009, Circulation research.

[30]  G. Sapkota,et al.  The specificities of small molecule inhibitors of the TGFß and BMP pathways. , 2011, Cellular signalling.

[31]  P. Khaw,et al.  Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome , 2003, Gene Therapy.

[32]  G. Wolf,et al.  TGF-beta and fibrosis in different organs - molecular pathway imprints. , 2009, Biochimica et biophysica acta.

[33]  K. Cutroneo.  TGF‐β–induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[34]  A. Weiss,et al.  Primary human dermal fibroblast interactions with open weave three-dimensional scaffolds prepared from synthetic human elastin. , 2009, Biomaterials.

[35]  D. Abraham,et al.  Connective Tissue Growth Factor Gene Regulation , 2003, The Journal of Biological Chemistry.

[36]  N. Uehara,et al.  Comparison of transforming growth factor-beta/Smad signaling between normal dermal fibroblasts and fibroblasts derived from central and peripheral areas of keloid lesions. , 2005, In vivo.

[37]  P. Khaw,et al.  Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. , 2003, Investigative ophthalmology & visual science.

[38]  G. Werther,et al.  Epidermal homeostasis: the role of the growth hormone and insulin-like growth factor systems. , 2003, Endocrine reviews.

[39]  Jonas Larsson,et al.  Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. , 2003, Molecular cell.

[40]  M. Pisano,et al.  Interaction of Smads with collagen types I, III, and V. , 2003, Biochemical and biophysical research communications.

[41]  F. Gao,et al.  Inhibition of PPAR-α activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-β/Smad3 , 2007 .

[42]  D. Dykxhoorn,et al.  Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.

[43]  D. Ladin,et al.  Acute and Chronic Animal Models for Excessive Dermal Scarring: Quantitative Studies , 1997, Plastic and reconstructive surgery.

[44]  S. Jabłońska,et al.  An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma. , 2004, Arthritis and rheumatism.

[45]  F. Hug,et al.  Fibronectin synthesis by human tubular epithelial cells in culture: effects of PDGF and TGF-beta on synthesis and splicing. , 1998, Kidney international.

[46]  D. Foreman,et al.  Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. , 1994, Journal of cell science.